Jump to content

Psilocybin mushroom

From Wikipedia, the free encyclopedia
(Redirected from Magic mushroom)
"Magic mushroom" redirects here. For other uses, see Magic mushroom (disambiguation).

Psilocybe semilanceata

Psilocybin mushrooms, commonly known as magic mushrooms,[1] shrooms, or broadly as hallucinogenic mushrooms, are a polyphyletic informal group of fungi that contain psilocybin, which turns into psilocin upon ingestion. The most potent species are members of genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens, but psilocybin has also been isolated from approximately a dozen other genera, including Panaeolus (including Copelandia), Inocybe, Pluteus, Gymnopilus, and Pholiotina.

Amongst other cultural applications, psilocybin mushrooms are used as recreational drugs. They may be depicted in Stone Age rock art in Africa and Europe, but are more certainly represented in pre-Columbian sculptures and glyphs seen throughout the Americas.

History

[edit]
Main article: Psilocybin § History

Psilocybin mushrooms have been[when?] and continue to be used in Mexican and Central American cultures in religious, divinatory, or spiritual contexts.[2]

Early

[edit]
Pre-Columbian mushroom stones

Rock art from c. 9000–7000 BCE from Tassili, Algeria, is believed to depict psychedelic mushrooms and the transformation of the user under their influence.[3] Prehistoric rock art near Villar del Humo in Spain suggests that Psilocybe hispanica was used in religious rituals 6,000 years ago.[4] The hallucinogenic[5] species of the Psilocybe genus have a history of use among the native peoples of Mesoamerica for religious communion, divination, and healing, from pre-Columbian times to the present day.[6] Mushroom stones and motifs have been found in Guatemala.[7] A statuette dating from c. 200 CE depicting a mushroom strongly resembling Psilocybe mexicana was found in the west Mexican state of Colima in a shaft and chamber tomb. A Psilocybe species known to the Aztecs as teōnanācatl (literally "divine mushroom": the agglutinative form of teōtl (god, sacred) and nanācatl (mushroom) in Nahuatl language) was reportedly served at the coronation of the Aztec ruler Moctezuma II in 1502. Aztecs and Mazatecs referred to psilocybin mushrooms as genius mushrooms, divinatory mushrooms, and wondrous mushrooms when translated into English.[8] Bernardino de Sahagún reported the ritualistic use of teonanácatl by the Aztecs when he traveled to Central America after the expedition of Hernán Cortés.[9]

After the Spanish conquest, Catholic missionaries campaigned against the cultural tradition of the Aztecs, dismissing the Aztecs as idolaters, and the use of hallucinogenic plants and mushrooms, together with other pre-Christian traditions, was quickly suppressed.[7] The Spanish believed the mushroom allowed the Aztecs and others to communicate with demons. Despite this history, the use of teonanácatl has persisted in some remote areas.[2]

Modern

[edit]
Psilocybe allenii

The first mention of hallucinogenic mushrooms in European medicinal literature was in the London Medical and Physical Journal in 1799: A man served Psilocybe semilanceata mushrooms he had picked for breakfast in London's Green Park to his family. The apothecary who treated them later described how the youngest child "was attacked with fits of immoderate laughter, nor could the threats of his father or mother refrain him."[10]

Psilocybe mexicana

In 1955, Valentina Pavlovna Wasson and R. Gordon Wasson became the first known European Americans to actively participate in an indigenous mushroom ceremony. The Wassons did much to publicize their experience, even publishing an article on their experiences in Life on May 13, 1957.[11] In 1956, Roger Heim identified the psychoactive mushroom the Wassons brought back from Mexico as Psilocybe,[12] and in 1958, Albert Hofmann first identified psilocybin and psilocin as the active compounds in these mushrooms.[13][14]

Inspired by the Wassons' Life article, Timothy Leary traveled to Mexico to experience psilocybin mushrooms himself. When he returned to Harvard in 1960, he and Richard Alpert started the Harvard Psilocybin Project, promoting psychological and religious studies of psilocybin and other psychedelic drugs. Alpert and Leary sought to conduct research with psilocybin on prisoners in the 1960s, testing its effects on recidivism.[15] This experiment reviewed the subjects six months later, and found that the recidivism rate had decreased beyond their expectation, below 40%. This, and another experiment administering psilocybin to graduate divinity students, showed controversy. Shortly after Leary and Alpert were dismissed from their jobs by Harvard in 1963, they turned their attention toward promoting the psychedelic experience to the nascent hippie counterculture.[16]

The popularization of entheogens by the Wassons, Leary, Terence McKenna, Robert Anton Wilson, and many others led to an explosion in the use of psilocybin mushrooms throughout the world. By the early 1970s, many psilocybin mushroom species were described from temperate North America, Europe, and Asia and were widely collected. Books describing methods of cultivating large quantities of Psilocybe cubensis were also published. The availability of psilocybin mushrooms from wild and cultivated sources has made them one of the most widely used psychedelic drugs.

At present, psilocybin mushroom use has been reported among some groups spanning from central Mexico to Oaxaca, including groups of Nahua, Mixtecs, Mixe, Mazatecs, Zapotecs, and others.[2] An important figure of mushroom usage in Mexico was María Sabina,[17] who used native mushrooms, such as Psilocybe mexicana in her practice.

Occurrence

[edit]
Main article: Psilocybin § Natural occurrence
Non-Psilocybe species of psilocybin mushroom include Pluteus salicinus (left), Gymnopilus luteoviridis (center), and Panaeolus cinctulus, formerly called Panaeolus subbalteatus (right)

In a 2000 review on the worldwide distribution of psilocybin mushrooms, Gastón Guzmán and colleagues considered these distributed among the following genera: Psilocybe (116 species), Gymnopilus (14), Panaeolus (13), Copelandia (12), Pluteus (6) Inocybe (6), Pholiotina (4) and Galerina (1).[18][19] Guzmán increased his estimate of the number of psilocybin-containing Psilocybe to 144 species in a 2005 review.

Global distribution of 100+ psychoactive species of genus Psilocybe mushrooms[20]

Many of them are found in Mexico (53 species), with the remainder distributed throughout Canada and the US (22), Europe (16), Asia (15), Africa (4), and Australia and associated islands (19).[21] Generally, psilocybin-containing species are dark-spored, gilled mushrooms that grow in meadows and woods in the subtropics and tropics, usually in soils rich in humus and plant debris.[22] Psilocybin mushrooms occur on all continents, but the majority of species are found in subtropical humid forests.[18] P. cubensis is the most common Psilocybe in tropical areas. P. semilanceata, considered the world's most widely distributed psilocybin mushroom,[23] is found in temperate parts of Europe, North America, Asia, South America, Australia and New Zealand, although it is absent from Mexico.[21]

Composition

[edit]

Magic mushroom composition varies from genus to genus and species to species.[24] Its principal component is psilocybin,[25] which is converted into psilocin to produce psychoactive effects.[26][27] Besides psilocin, norpsilocin, baeocystin, norbaeocystin, and aeruginascin may also be present, which can modify the effects of magic mushrooms.[24] Panaeolus subbalteatus, one species of magic mushroom, had the highest amount of psilocybin compared to the rest of the fruiting body.[24] Certain mushrooms are found to produce beta-carbolines which inhibit monoamine oxidase, an enzyme that breaks down tryptamine alkaloids. They occur in different genera, such as Psilocybe,[28]Cyclocybe,[29] and Hygrophorus.[30] Harmine, harmane, norharmane and a range of other l-tryptophan-derived β-carbolines were discovered in Psilocybe species.

Effects

[edit]
Main article: Psilocybin § Pharmacology
Table from the 2010 DrugScience study ranking various drugs (legal and illegal) based on statements by drug-harm experts. This study rated "mushroom" the least harmful drug overall and for users, and the only drug that did not get any scores for harm on others.[31]

The effects of psilocybin mushrooms come from psilocybin and psilocin. When psilocybin is ingested, it is broken down by the liver in a process called dephosphorylation. The resulting compound is called psilocin, responsible for the psychedelic effects.[32] Psilocybin and psilocin create short-term increases in tolerance of users, thus making it difficult to misuse them because the more often they are taken within a short period, the weaker the resultant effects are.[33] Psilocybin mushrooms have not been known to cause physical or psychological dependence (addiction).[34] The psychedelic effects appear around 20 minutes after ingestion and can last up to 6 hours. Physical effects may occur, including nausea, vomiting, euphoria, muscle weakness or relaxation, drowsiness, and lack of coordination.

As with many psychedelic substances, the effects of psychedelic mushrooms are subjective and can vary considerably among individual users. The mind-altering effects of psilocybin-containing mushrooms typically last from three to eight hours, depending on dosage, preparation method, and personal metabolism. The first 3–4 hours after ingestion are typically referred to as the 'peak'—in which the user experiences more vivid visuals and distortions in reality. The effects can seem to last much longer for the user because of psilocybin's ability to alter time perception.[35]

Sensory

[edit]

Sensory effects include visual and auditory hallucinations followed by emotional changes and altered perception of time and space.[36] Noticeable changes to the auditory, visual, and tactile senses may become apparent around 30 minutes to an hour after ingestion, although effects may take up to two hours to take place. These shifts in perception visually include enhancement and contrasting of colors, strange light phenomena (such as auras or "halos" around light sources), increased visual acuity, surfaces that seem to ripple, shimmer, or breathe; complex open and closed eye visuals of form constants or images, objects that warp, morph, or change solid colors; a sense of melting into the environment, and trails behind moving objects. Sounds may seem to have increased clarity—music, for example, can take on a profound sense of cadence and depth.[36] Some users experience synesthesia, wherein they perceive, for example, a visualization of color upon hearing a particular sound.[37]

Emotional

[edit]

As with other psychedelics such as LSD, the experience, or 'trip,' is strongly dependent upon set and setting.[36] Hilarity, lack of concentration, and muscular relaxation (including dilated pupils) are all normal effects, sometimes in the same trip.[36] A negative environment could contribute to a bad trip, whereas a comfortable and familiar environment would set the stage for a pleasant experience. Psychedelics make experiences more intense, so if a person enters a trip in an anxious state of mind, they will likely experience heightened anxiety on their trip. Many users find it preferable to ingest the mushrooms with friends or people familiar with 'tripping.'[38] The psychological consequences of psilocybin use include hallucinations and an inability to discern fantasy from reality. Panic reactions and psychosis also may occur, particularly if a user ingests a large dose.[39]

Dosage

[edit]
Main article: Psilocybin § Pharmacokinetics
A bag of 1.5 grams of dried psilocybe cubensis mushrooms

The dosage of mushrooms containing psilocybin depends on the psilocybin and psilocin content, which can vary significantly between and within the same species but is typically around 0.5–2.0% of the dried weight of the mushroom.[40] Usual doses of the common species Psilocybe cubensis range around 1.0 to 2.5 g, while about 2.5 to 5.0 g dried mushroom material is considered a strong dose.[41] Above 5 g is often considered a heavy dose, with 5.0 grams of dried mushroom often being referred to as a "heroic dose".[42][43]

However, microdosing has become a popular technique for many users, which involves taking <1.0g for an experience that is not as intense or powerful, but recreationally enjoyable and even alleviating for symptoms of depression.[44]

The concentration of active psilocybin mushroom compounds varies from species to species but also from mushroom to mushroom within a given species, subspecies or variety.[45] The species Psilocybe azurescens contains the most psilocybin (up to 1.78%).

Toxicology

[edit]

The species within the most commonly foraged and ingested genus of psilocybin mushrooms, the psilocybe, contains two primary hallucinogenic toxins; psilocybin and psilocin.[46] The median lethal dose, also known as "LD50", of psilocybin is 280 mg/kg.[47]

From a toxicological profile, it would be incredibly difficult to overdose on psilocybin mushrooms, given their primary toxin compounds. To consume such massive amounts of psilocybin, one must ingest more than 1.2 kg of dried Psilocybe cubensis given 1-2% of the dried mushroom contains psilocybin.[40]

Posing a more realistic threat than a lethal overdose, significantly elevated levels of psilocin can overstimulate the 5-HT2A receptors in the brain, causing acute serotonin syndrome.[48] A 2015 study observed that a dose of 200 mg/kg psilocin induced symptoms of acute serotonin poisoning in mice.[49]

Neurotoxicity-induced fatal events are uncommon with psilocybin mushroom overdose, as most patients admitted to critical care are released from the department only requiring moderate treatment.[48] However, fatal events related to emotional distress and trip-induced psychosis can occur as a result of over-consumption of psilocybin mushrooms. In 2003, a 27-year-old man was found dead in an irrigation canal due to hypothermia. In his bedroom was found two cultivation pots of psilocybin mushrooms, but no report of toxicology was made.[50]

Clinical research

[edit]

Due partly to restrictions of the Controlled Substances Act, research in the United States was limited until the early 21st century when psilocybin mushrooms were tested for their potential to treat drug dependence, anxiety and mood disorders.[51][52] In 2018–19, the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for studies of psilocybin in depressive disorders.[53]

Legality

[edit]
Main article: Legal status of psilocybin mushrooms

The legality of the cultivation, possession, and sale of psilocybin mushrooms and psilocybin and psilocin varies from country to country.

After Oregon Measure 109, in 2020, Oregon became the first US state to decriminalize psilocybin and legalize it for therapeutic use. However, selling psilocybin without being licensed may still attract fines or imprisonment.[54] In 2022 Colorado legalized consumption, growing, and sharing for personal use,[55] though sales are prohibited while regulations are being drafted.[56][57] Other jurisdictions in the United States where psilocybin mushrooms are decriminalized include Ann Arbor and Detroit, Michigan; Oakland and Santa Cruz, California; Easthampton, Somerville, Northampton, and Cambridge, Massachusetts; Seattle, Washington; and Washington, DC.

Furthermore, buying spores of mushroom species containing psilocybin online in the United States is legal in all states except Georgia, Idaho and California.[58] This is because only fruiting mushrooms and mycelium contain psilocybin, a federally banned substance.[59] A technical caveat to consider, however, is that the distributed spores must not be intended to be used for cultivation, but allowed for microscopy purposes.[60]

United Nations

[edit]
Main article: Convention on Psychotropic Substances
Article 32 makes an exception for psilocybin mushroom and other wild psychotropic plants, to protect use in religious rituals in case such plants themselves were in the future added to Schedule I.

Internationally, mescaline, DMT, and psilocin, are Schedule I drugs under the Convention on Psychotropic Substances. The Commentary on the Convention on Psychotropic Substances notes, however, that the plants containing them are not subject to international control:[61]

The cultivation of plants from which psychotropic substances are obtained is not controlled by the Vienna Convention... Neither the crown (fruit, mescal button) of the Peyote cactus nor the roots of the plant Mimosa hostilis nor Psilocybe mushrooms themselves are included in Schedule 1, but only their respective principals, mescaline, DMT, and psilocin.

See also

[edit]

Citations

[edit]
  1. ^ Wennig, R; Eyer, F; Schaper, A; Zilker, T; Andresen-Streichert, H (2020). "Mushroom Poisoning". Deutsches Ärzteblatt International. 117 (42): 701–708. doi:10.3238/arztebl.2020.0701. PMC 7868946. PMID 33559585.
  2. ^ a b c Guzmán G. (2008). "Hallucinogenic mushrooms in Mexico: An overview". Economic Botany. 62 (3): 404–412. Bibcode:2008EcBot..62..404G. doi:10.1007/s12231-008-9033-8. S2CID 22085876.
  3. ^ Samorini, Giorgio (1992). "The oldest representations of hallucinogenic mushrooms in the world (Sahara Desert, 9000-7000 BP)". Integration. Zeitschrift für geistbewegende Pflanzen und Kultur. 2/3: 69–75.[permanent dead link‍]
  4. ^ Akers, Brian P.; Ruiz, Juan Francisco; Piper, Alan; Ruck, Carl A. P. (2011). "A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms?1". Economic Botany. 65 (2): 121–128. doi:10.1007/s12231-011-9152-5. S2CID 3955222.
  5. ^ Abuse, National Institute on Drug (April 22, 2019). "Hallucinogens DrugFacts". National Institute on Drug Abuse. Archived from the original on December 26, 2018. Retrieved December 27, 2020.
  6. ^ F.J. Carod-Artal (January 1, 2015). "Hallucinogenic drugs in pre-Columbian Mesoamerican cultures". Neurología (English Edition). 30 (1): 42–49. doi:10.1016/j.nrleng.2011.07.010. PMID 21893367.
  7. ^ a b Stamets (1996), p. 11.
  8. ^ Stamets (1996), p. 7.
  9. ^ Hofmann A. (1980). "The Mexican relatives of LSD". LSD: My Problem Child. New York City: McGraw-Hill. pp. 49–71. ISBN 978-0-07-029325-0.
  10. ^ Brande E. (1799). "Mr. E. Brande, on a poisonous species of Agaric". The Medical and Physical Journal: Containing the Earliest Information on Subjects of Medicine, Surgery, Pharmacy, Chemistry, and Natural History. 3 (11): 41–44. PMC 5659401. PMID 30490162. Archived from the original on February 24, 2024. Retrieved October 19, 2016.
  11. ^ Wasson RG (1957). "Seeking the magic mushroom". Life. No. May 13. pp. 100–120. Archived from the original on February 24, 2024. Retrieved October 19, 2016.
  12. ^ Heim R. (1957). "Notes préliminaires sur les agarics hallucinogènes du Mexique" [Preliminary notes on the hallucination-producing agarics of Mexico]. Revue de Mycologie (in French). 22 (1): 58–79.
  13. ^ Hofmann A, Frey A, Ott H, Petrzilka T, Troxler F (1958). "Konstitutionsaufklärung und Synthese von Psilocybin" [The composition and synthesis of psilocybin]. Cellular and Molecular Life Sciences (in German). 14 (11): 397–399. doi:10.1007/BF02160424. PMID 13609599. S2CID 33692940.
  14. ^ Hofmann A, Heim R, Brack A, Kobel H (1958). "Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rauschpilz Psilocybe mexicana Heim" [Psilocybin, a psychotropic drug from the Mexican magic mushroom Psilocybe mexicana Heim]. Experientia (in German). 14 (3): 107–109. doi:10.1007/BF02159243. PMID 13537892. S2CID 42898430.
  15. ^ "Dr. Leary's Concord Prison Experiment: A 34-Year Follow-Up Study". Bulletin of the Multidisciplinary Association for Psychedelic Studies. 9 (4): 10–18. 1999. Archived from the original on March 23, 2021. Retrieved March 26, 2021.
  16. ^ Lattin, Don (2010). The Harvard Psychedelic Club: How Timothy Leary, Ram Dass, Huston Smith, and Andrew Weil killed the fifties and ushered in a new age for America (1st ed.). New York: HarperOne. pp. 37–44. ISBN 978-0-06-165593-7.
  17. ^ Monaghan, John D.; Cohen, Jeffrey H. (2000). "Thirty years of Oaxacan ethnography". In Monaghan, John; Edmonson, Barbara (eds.). Ethnology. Austin, Texas: University of Texas Press. p. 165. ISBN 978-0-292-70881-5.
  18. ^ a b Guzmán, G.; Allen, J.W.; Gartz, J. (2000). "A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion" (PDF). Annali del Museo Civico di Rovereto: Sezione Archeologia, Storia, Scienze Naturali. 14: 189–280. Archived (PDF) from the original on February 5, 2018. Retrieved April 5, 2022.
  19. ^ Gotvaldova, Klara; Borovicka, Jan; Hajkova, Katerina; Cihlarova, Petra; Rockefeller, Alan; Kuchar, Martin (2022). "Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids". International Journal of Molecular Sciences. 23 (22): 14068. doi:10.3390/ijms232214068. ISSN 1422-0067. PMC 9693126. PMID 36430546.
  20. ^ Guzmán G, Allen JW, Gartz J (1998). "A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion" (PDF). Annali del Museo Civico di Rovereto. 14: 207. Archived (PDF) from the original on June 26, 2010. Retrieved September 17, 2017.
  21. ^ a b Guzmán, G. (2005). "Species diversity of the genus Psilocybe (Basidiomycotina, Agaricales, Strophariaceae) in the world mycobiota, with special attention to hallucinogenic properties". International Journal of Medicinal Mushrooms. 7 (1–2): 305–331. doi:10.1615/intjmedmushr.v7.i12.280.
  22. ^ Wurst, M.; Kysilka, R.; Flieger, M. (2002). "Psychoactive tryptamines from Basidiomycetes". Folia Microbiologica. 47 (1): 3–27 [5]. doi:10.1007/BF02818560. PMID 11980266. S2CID 31056807.
  23. ^ Guzmán, G. (1983). The Genus Psilocybe: A Systematic Revision of the Known Species Including the History, Distribution, and Chemistry of the Hallucinogenic Species. Beihefte Zur Nova Hedwigia. Vol. 74. Vaduz, Liechtenstein: J. Cramer. pp. 361–2. ISBN 978-3-7682-5474-8.
  24. ^ a b c "Chemical Composition Variability in Magic Mushrooms". Psychedelic Science Review. March 4, 2019. Archived from the original on August 18, 2021. Retrieved August 17, 2021.
  25. ^ "Hallucinogenic mushrooms drug profile". European Monitoring Centre for Drugs and Drug Addiction. Archived from the original on August 17, 2021. Retrieved August 17, 2021.
  26. ^ Kuhn, Cynthia; Swartzwelder, Scott; Wilson, Wilkie (2003). Buzzed: The Straight Facts about the Most Used and Abused Drugs from Alcohol to Ecstasy. W.W. Norton & Company. p. 83. ISBN 978-0-393-32493-8.
  27. ^ Canada, Health (January 12, 2012). "Magic mushrooms – Canada.ca". www.canada.ca. Archived from the original on December 22, 2017. Retrieved December 20, 2017.
  28. ^ Blei F, Dörner S, Fricke J, Baldeweg F, Trottmann F, Komor A, Meyer F, Hertweck C, Hoffmeister D (January 2020). "Simultaneous Production of Psilocybin and a Cocktail of β-Carboline Monoamine Oxidase Inhibitors in 'Magic' Mushrooms". Chemistry: A European Journal. 26 (3): 729–734. doi:10.1002/chem.201904363. PMC 7003923. PMID 31729089.
  29. ^ Krüzselyi D, Vetter J, Ott PG, Darcsi A, Béni S, Gömöry Á, Drahos L, Zsila F, Móricz ÁM (September 2019). "Isolation and structural elucidation of a novel brunnein-type antioxidant β-carboline alkaloid from Cyclocybe cylindracea". Fitoterapia. 137: 104180. doi:10.1016/j.fitote.2019.104180. PMID 31150766. S2CID 172137046.
  30. ^ Teichert A, Lübken T, Schmidt J, Kuhnt C, Huth M, Porzel A, Wessjohann L, Arnold N (2008). "Determination of beta-carboline alkaloids in fruiting bodies of Hygrophorus spp. by liquid chromatography/electrospray ionization tandem mass spectrometry". Phytochemical Analysis. 19 (4): 335–41. Bibcode:2008PChAn..19..335T. doi:10.1002/pca.1057. PMID 18401852.
  31. ^ Nutt DJ, King LA, Phillips LD (November 2010). "Drug harms in the UK: a multicriteria decision analysis". Lancet. 376 (9752): 1558–1565. CiteSeerX 10.1.1.690.1283. doi:10.1016/S0140-6736(10)61462-6. PMID 21036393. S2CID 5667719.
  32. ^ Passie, T.; Seifert, J.; Schneider, und; Emrich, H.M. (2002). "The pharmacology of psilocybin". Addiction Biology. 7 (4): 357–364. doi:10.1080/1355621021000005937. PMID 14578010. S2CID 12656091.
  33. ^ "Psilocybin Fast Facts". National Drug Intelligence Center. Archived from the original on May 12, 2007. Retrieved April 4, 2007.
  34. ^ van Amsterdam, J.; Opperhuizen, A.; van den Brink, W. (2011). "Harm potential of magic mushroom use: A review". Regulatory Toxicology and Pharmacology. 59 (3): 423–429. doi:10.1016/j.yrtph.2011.01.006. PMID 21256914.
  35. ^ Wittmann, M.; Carter, O.; Hasler, F.; Cahn, B.R.; Grimberg, und; Spring, P.; Hell, D.; Flohr, H.; Vollenweider, F.X. (2007). "Effects of psilocybin on time perception and temporal control of behavior in humans". Journal of Psychopharmacology. 21 (1): 50–64. doi:10.1177/0269881106065859. PMID 16714323. S2CID 3165579.
  36. ^ a b c d Schultes, Richard Evans (1976). Hallucinogenic Plants. Illustrated by Elmer W. Smith. New York: Golden Press. p. 68. ISBN 978-0-307-24362-1.
  37. ^ Ballesteros, S.; Ramón, M.F.; Iturralde, M.J.; Martínez-Arrieta, R. (2006). "Natural Sources of Drugs of Abuse: Magic Mushrooms". In Cole, S.M. (ed.). New Research on Street Drugs. Nova Science Publishers. p. 175. ISBN 978-1-59454-961-8. Archived from the original on February 24, 2024. Retrieved October 19, 2016.
  38. ^ Stamets (1996)
  39. ^ "Psilocybin Fast Facts". National Drug Intelligence Center, US Department of Justice. Archived from the original on May 3, 2018. Retrieved May 3, 2018. Public Domain This article incorporates text from this source, which is in the public domain.
  40. ^ a b Laussmann, Tim; Meier-Giebing, Sigrid (2010). "Forensic analysis of hallucinogenic mushrooms and khat (Catha edulisForsk) using cation-exchange liquid chromatography". Forensic Science International. 1 (3): 160–164. doi:10.1016/j.forsciint.2009.12.013. PMID 20047807.
  41. ^ Erowid (2006). "Erowid Psilocybin Mushroom Vault: Dosage" (shtml). Erowid. Archived from the original on December 23, 2023. Retrieved November 26, 2006.
  42. ^ "Terence McKenna's Last Trip". Wired Magazine. Condé Nast Publications. May 1, 2000. Archived from the original on March 14, 2014. Retrieved September 17, 2017.
  43. ^ |title=Microdosing vs Full Dose: A Comparative Analysis |date=July 30, 2024 |Michael Griswold |access-date=August 4, 2024 |archive-date=October 8, 2024
  44. ^ Dana G Smith (2022). "More People Are Microdosing for Mental Health. But Does It Work?" (shtml). The New York Times. Retrieved July 31, 2024.
  45. ^ Bigwood J, Beug MW (1982). "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer". Journal of Ethnopharmacology. 5 (3): 287–291. doi:10.1016/0378-8741(82)90014-9. PMID 7201054.
  46. ^ Kosentka, Pawel (2013). "Evolution of the toxins muscarine and psilocybin in a family of mushroom-forming fungi". PLOS ONE. 8 (5): e64646. Bibcode:2013PLoSO...864646K. doi:10.1371/journal.pone.0064646. PMC 3662758. PMID 23717644.
  47. ^ Maryadele, O'Neil (2006). The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. Merck Research Laboratories. ISBN 978-0911910001.
  48. ^ a b Chilton, Scott; Bigwood, Jeremy (1979). "Chilton, W. Scott, Jeremy Bigwood, and Robert E. Jensen. "Psilocin, bufotenine, and serotonin: historical and biosynthetic observations". Journal of Psychedelic Drugs. 11.1 (2): 61–69. doi:10.1080/02791072.1979.10472093. PMID 392119. Archived from the original on December 24, 2022. Retrieved December 24, 2022.
  49. ^ Zhuk, Olga (2015). "Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice". Toxins. 7 (4): 1018–1029. doi:10.3390/toxins7041018. PMC 4417952. PMID 25826052.
  50. ^ Lima, Afonso DL (2012). "Poisonous mushrooms; a review of the most common intoxications" (PDF). Nutricion Hospitalaria. 27 (2): 402–408. doi:10.3305/nh.2012.27.2.5328. PMID 22732961. Archived (PDF) from the original on December 24, 2022. Retrieved December 24, 2022.
  51. ^ Bui, Eric; King, Franklin; Melaragno, Andrew (December 1, 2019). "Pharmacotherapy of anxiety disorders in the 21st century: A call for novel approaches (Review)". General Psychiatry. 32 (6): e100136. doi:10.1136/gpsych-2019-100136. PMC 6936967. PMID 31922087.
  52. ^ Doblin, Richard E.; Christiansen, Merete; Jerome, Lisa; Burge, Brad (March 15, 2019). "The Past and Future of Psychedelic Science: An Introduction to This Issue". Journal of Psychoactive Drugs. 51 (2): 93–97. doi:10.1080/02791072.2019.1606472. ISSN 0279-1072. PMID 31132970. S2CID 167220251.
  53. ^ "FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive disorder". Business Wire. November 22, 2019. Archived from the original on October 26, 2021. Retrieved September 17, 2020.
  54. ^ "Oregon Measure 109, Psilocybin Mushroom Services Program Initiative (2020)". ballotpedia.org. November 3, 2020. Archived from the original on January 5, 2023. Retrieved January 4, 2023.
  55. ^ Brown, Jennifer (November 10, 2022). "Colorado becomes second state to legalize "magic mushrooms"". The Colorado Sun. Archived from the original on November 10, 2022. Retrieved November 10, 2022.
  56. ^ "A gray market emerges in Colorado after voters approved psychedelic substances". NPR. Archived from the original on July 5, 2023. Retrieved July 5, 2023.
  57. ^ "Colorado Proposition 122, Decriminalization and Regulated Access Program for Certain Psychedelic Plants and Fungi Initiative (2022)". ballotpedia.org. November 8, 2022. Archived from the original on July 20, 2023. Retrieved July 5, 2023.
  58. ^ "Frequently Asked Questions". sporestock.com. July 2, 2022. Archived from the original on January 5, 2023. Retrieved January 4, 2023.
  59. ^ "Psilocybin Drug Fact Sheet" (PDF). dea.gov. April 21, 2020. Archived (PDF) from the original on January 5, 2023. Retrieved January 4, 2023.
  60. ^ "COURT OF APPEALS OF WISCONSIN PUBLISHED OPINION" (PDF). wicourts.gov. June 21, 2007. Archived (PDF) from the original on March 26, 2023. Retrieved January 4, 2023.
  61. ^ DMT – UN report, MAPS, March 31, 2001, archived from the original on January 21, 2012, retrieved January 14, 2012

General and cited references

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Psilocybin_mushroom&oldid=1264053383"